Neurocrine Biosciences Reports Record Q3 Sales Driven by INGREZZA
Neurocrine Biosciences (NBIX) reported record net product sales exceeding $1.1 billion for the third quarter, achieving record profitability under the leadership of CEO Kyle Gano. The company's performance was primarily driven by strong momentum from its key product, INGREZZA. Looking ahead to 2027, management expects double-digit volume growth for INGREZZA. This projected growth is intended to offset anticipated net pricing headwinds, which are expected to be in the mid-to-high single-digit range.
Tickers: $NBIX